Exploring the effect of deucravacitinib in patients with palmoplantar pustular psoriasis
Current therapeutic options for PPPP are limited, necessitating exploration of novel treatments. Deucravacitinib's mechanism of action, targeting TYK2, could show promise in PPPP management. However, its efficacy and safety in this specific condition require further investigation through larger, randomized controlled trials.
Authors
- Sascha Ständer (ORCID: https://orcid.org/0000-0003-0183-0375)
- David A. De Luca (ORCID: https://orcid.org/0000-0002-2107-301X)
- Cristian Papara (ORCID: https://orcid.org/0000-0001-7315-4711)
- Tomasz Hawro (ORCID: https://orcid.org/0000-0001-9990-1332)
- Diamant Thaçi (ORCID: https://orcid.org/0000-0001-8513-550X)
Institutions
- University Hospital Schleswig-Holstein (DE)
- University of Lübeck (DE)
Publication Details
- Journal
- Journal of Dermatological Treatment
- Published
- 2024-09-10
- DOI
- https://doi.org/10.1080/09546634.2024.2399220
- Citations
- 12
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 2.89